0001562180-23-006088.txt : 20230801
0001562180-23-006088.hdr.sgml : 20230801
20230801163524
ACCESSION NUMBER: 0001562180-23-006088
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230731
FILED AS OF DATE: 20230801
DATE AS OF CHANGE: 20230801
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Snow Ellen
CENTRAL INDEX KEY: 0001786643
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36352
FILM NUMBER: 231132301
MAIL ADDRESS:
STREET 1: C/O PEAR THERAPEUTICS, INC.
STREET 2: 200 STATE STREET, 13TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02109
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akebia Therapeutics, Inc.
CENTRAL INDEX KEY: 0001517022
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 208756903
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 245 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-871-2098
MAIL ADDRESS:
STREET 1: 245 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0508
4
2023-07-31
false
0001517022
Akebia Therapeutics, Inc.
AKBA
0001786643
Snow Ellen
C/O AKEBIA THERAPEUTICS, INC
245 FIRST ST.
CAMBRIDGE
MA
02142
false
true
false
false
SVP, CFO and Treasurer
false
Common Stock
2023-07-31
4
A
false
370000.00
0.00
A
370000.00
D
Stock Option (Right to buy)
1.67
2023-07-31
4
A
false
560000.00
0.00
A
2033-07-31
Common Stock
560000.00
560000.00
D
The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the RSUs will vest upon each of the first, second and third anniversaries of the grant date, subject to the Reporting Person's continued service with the Issuer.
The options were granted by the Issuer as an inducement material to the Reporting Person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer.
/s/Carolyn Rucci, attorney-in-fact for Ellen Snow
2023-08-01